Efficacy and Safety of SBRT Followed by Tislelizumab Plus Cetuximab and Irinotecan in Patients With Previously Treated RAS Wild-type Advanced Refractory Colorectal Cancer

Fujian Provincial Cancer Hospital

Status and phase

Not yet enrolling

Phase 2

Conditions

Colorectal Cancer

Treatments

Drug: Irinotecan Hydrochloride

Drug: Tislelizumab

Drug: cetuximab

Radiation: SBRT

Study type

Interventional

Funder types

Other

Identifiers

NCT05799443

STEC

Details and patient eligibility

About

To evaluate the efficacy and safety of SBRT followed by tislelizumab plus cetuximab and irinotecan in patients with previously treated RAS wild-type advanced refractory colorectal cancer

Enrollment

23 estimated patients

Sex

All

Ages

18 to 75 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Aged 18-75 years
Physical Condition Score (ECOG PS) of the Eastern Cancer Cooperative Group (USA) 0 or 1;
Colorectal cancer diagnosed histologically and/or cytologically has metastases or relapses that are not curable by surgery
Have received first - and second-line systemic antitumor therapy for mCRC (chemotherapy drugs may include fluorouracil, oxaliplatin, irinotecan, e.g. XELOX, FOLFOX, FOLFIRI, FOLFOXIRI, XELIRI; Can be combined with or without targeted drugs, such as cetuximab, bevacizumab);And disease progression after second-line treatment;
Evaluation of lung or liver metastases can be evaluated, with stereotactic radiotherapy maneuverability;
At least one measurable lesion as defined in RECIST version 1.1;
Fertile patients must be willing to take effective pregnancy avoidance measures during the study period and ≥120 days after the last dose; Female patients with negative urine or serum pregnancy test results within 7 days or less before the first administration of the study drug;
Have fully understood this study and voluntarily signed informed consent.
Adequate organ and bone marrow function, meeting the following definitions:
1. Blood routine (no blood transfusion, no granulocyte colony stimulating factor [G-CSF], no other drug correction within 14 days before treatment);Absolute count of neutrophils (ANC) ≥1.5×109/L;Hemoglobin (HB) ≥9.0 g/dL;Platelet count (PLT) ≥80×109/L;
2. Blood biochemistry, serum creatinine (Cr) ≤ 1.5× upper limit of normal (ULN) or creatinine clearance ≥60 mL/min;Serum albumin ≥2.8g/dL, for patients with poor nutritional status before neoadjuvant therapy, patients who met the requirements through parenteral nutrition could also be included in the group;Total bilirubin (TBIL) ≤ 1.5×ULN;Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) level ≤2.5×ULN;

Exclusion criteria

1. Pregnant or lactating women;
Patients with a known history of allergy to any investigative drug, similar drug or excipient;
Patients with risk of massive gastrointestinal bleeding or gastrointestinal obstruction;
Patients with a history of thromboembolism, except thrombosis caused by PICC;
There are patients with active infection;
Patients with unmanageable hypertension (systolic blood pressure ≥160 mmHg and diastolic blood pressure ≥90mmHg);
Patients with brain metastases with clinical symptoms or imaging evidence;
Contraindications exist in treatment with other chronic diseases;
Patients with a history of immunotherapy-related myocarditis, pneumonia, colitis, hepatitis, nephritis, etc., with current AE ≥ grade 2;
According to the evaluation criteria of NCI CTCAE version 5.0, there are patients with all kinds of toxicities ≥ grade 2 due to previous treatment;
Other conditions that the researchers determined were not suitable for inclusion in the study.
Received any antitumor therapy and participated in other clinical studies within 4 weeks before enrollment.